公开(公告)号：WO2017059371A1

公开(公告)日：2017-04-06

申请号：PCT/US2016/055017

申请日：2016-09-30

Applicant: AMGEN INC.

Inventor： XU, Jing ,  STANISLAUS, Shanaka ,  CHEN, Mei-Hsiu M. ,  HALE, Clarence H. ,  VENIANT-ELLISON, Murielle

IPC: A61K38/18 ,  A61P1/16

CPC classification number: A61K38/1825

Abstract: The invention relates method of treating a patient in need thereof with a long acting agonist to the FGF21 signaling pathway. In a particular embodiment, the invention relates to the use of molecules that stimulate the FGF21 signaling pathway, such as long acting FGF21 polypeptides or agonist antibodies, to treat disorders or diseases associated with excess bile acid. The invention further relates to pharmaceutical formulations and dosing of long acting agonists of the FGF21 signaling pathway suitable for treating bile acid related disorders.

Abstract translation: 本发明涉及将有需要的患者用长效激动剂治疗FGF21信号通路的方法。 在一个具体实施方案中，本发明涉及刺激FGF21信号传导途径的分子（例如长效FGF21多肽或激动剂抗体）用于治疗与过量胆汁酸相关的疾病或疾病的用途。 本发明还涉及适用于治疗胆汁酸相关疾病的FGF21信号传导途径的长效激动剂的药物制剂和给药。